Decreased plasma β‐amyloid in the Alzheimer's disease APP A 673 T variant carriers
Abstract
We investigated the association of Alzheimer's disease (AD)-related rare variants APP A673T and ABCA7 rs200538373-C with the levels of β-amyloid (Aβ) and parameters of metabolic and cardiovascular health in a population-based cohort of healthy middle-aged and elderly men. Carriers of protective APP A673T variant had, on average, 28% lower levels of Aβ40 and Aβ42 in plasma as compared to the controls and the carriers of ABCA7 rs200538373-C. This is the first report to show decreased Aβ levels in plasma in APP A673T carriers and thus provides evidence that lower Aβ levels throughout life may be protective against AD. Ann Neurol 2017;82:128-132.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The E682K APP mutation favors Aβ production by suppressing β' cleavage and favoring β cleavage.
“In addition, the E682K mutation in APP, located at the P1, β site, favors Aβ production by suppressing the cleavage at the β’ site to favor cleavage at the β site (12,13).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [13]
The A673T mutation is associated with 20% to 30% lower soluble APPβ levels compared with controls.
“In particular, the A673T mutation is associated with a different BACE1 recognition motif at the position P2 (A673T), resulting in 20% to 30% lower soluble APPβ (sAPPβ) levels compared with control subjects (12,13).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [13]
Human carriers of the A673T variant have about 28% lower plasma Aβ40 and Aβ42 levels than controls.
“carriers of the A673T variant in humans have about 28% lower levels of Aβ40 and Aβ42 in plasma compared with control subjects (12,13).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [13]
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · see citing works
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · see citing works
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626 · see citing works
Alzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473 · see citing works
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434 · see citing works
Stančáková, A., Javorský, M., Kuulasmaa, T., Haffner, S. M., Kuusisto, J., & Laakso, M. (2009) · Diabetes · doi:10.2337/db08-1607 · Cited by 348 · see citing works
Self-citationLoss-of-function variants in ABCA7 confer risk of Alzheimer's disease
DemGene, Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., Sulem, P., Magnusson, O. T., Gudjonsson, S. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3246 · Cited by 324 · see citing works
Self-citationCederberg, H., Stančáková, A., Yaluri, N., Modi, S. R., Kuusisto, J., & Laakso, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3528-5 · Cited by 316 · see citing works
Self-citationHansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andréasson, U., Londos, E., Wallin, A., Minthon, L., & Blennow, K. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.027 · Cited by 276 · see citing works
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gutierrez Gomez, M., Langois, C. M., Langbaum, J. B. S., Roontiva, A., Thiyyagura, P., Lee, W., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3314 · Cited by 177 · see citing works
Cuyvers, E., De Roeck, A., Van den Bossche, T., Van Cauwenberghe, C., Bettens, K., Vermeulen, S., Mattheijssens, M., Peeters, K., Engelborghs, S., Vandenbulcke, M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00133-7 · Cited by 152 · see citing works
ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology
Sakae, N., Liu, C., Shinohara, M., Frisch‐Daiello, J. L., Ma, L., Yamazaki, Y., Tachibana, M., Younkin, L. H., Kurti, A., Carrasquillo, M. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3757-15.2016 · Cited by 146 · see citing works
Stančáková, A., Paananen, J., Soininen, P., Kangas, A. J., Bonnycastle, L. L., Morken, M. A., Collins, F. S., Jackson, A., Boehnke, M., Kuusisto, J., et al. (2011) · Diabetes · doi:10.2337/db10-1655 · Cited by 92 · see citing works
Self-citationMartiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.003 · Cited by 70 · see citing works
Self-citation<i>ABCA7</i> rare variants and Alzheimer disease risk
Le Guennec, K., Nicolas, G., Quenez, O., Charbonnier, C., Wallon, D., Bellenguez, C., Grenier-Boley, B., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002627 · Cited by 69 · see citing works
Rarity of the Alzheimer Disease–ProtectiveAPPA673T Variant in the United States
Wang, L.-S., Naj, A. C., Graham, R., Crane, P. K., Kunkle, B. W., Cruchaga, C., Murcia, J. D. G., Cannon‐Albright, L., Baldwin, C. T., Zetterberg, H., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2157 · Cited by 47 · see citing works
Ting, S. K. S., Chong, M.-S., Kandiah, N., Hameed, S., Tan, L., Au, W.-L., Prakash, K. M., Pavanni, R., Lee, T.-S., Foo, J.-N., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.012 · Cited by 26 · see citing works
Kokawa, A., Ishihara, S., Fujiwara, H., Nobuhara, M., Iwata, M., Ihara, Y., & Funamoto, S. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0247-6 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · see citing works
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,771 · see citing works
The β-Secretase BACE1 in Alzheimer’s Disease
Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694 · see citing works
Solving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324 · see citing works
The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics
De Roeck, A., Van Broeckhoven, C., & Sleegers, K. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01994-1 · Cited by 212 · see citing works
Vergallo, A., Mégret, L., Lista, S., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., Vos, A. D., Habert, M., Potier, M., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.03.009 · Cited by 173 · see citing works
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P., Bateman, R., Carrillo, M., de Strooper, B., Haass, C., Reiman, E., Sperling, R., Tariot, P., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 129 · see citing works
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135 · see citing works
Koelsch, G. (2017) · Molecules · doi:10.3390/molecules22101723 · Cited by 125 · see citing works
Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer’s Disease
Marttinen, M., Takalo, M., Natunen, T., Wittrahm, R., Gabbouj, S., Kemppainen, S., Leinonen, V., Tanila, H., Haapasalo, A., & Hiltunen, M. O. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00963 · Cited by 86 · see citing works
Self-citationCai, W., Li, L., Sang, S., Pan, X., & Zhong, C. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-022-00985-9 · Cited by 83 · see citing works
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67 · see citing works
Li, N.-M., Li, N., Liu, K., Zhang, H.-H., Nakanishi, H., & Qing, H. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.247469 · Cited by 66 · see citing works
Serotonin, β‐amyloid, and cognition in Parkinson disease
Kotagal, V., Spino, C., Bohnen, N. I., Koeppe, R., & Albin, R. L. (2018) · Annals of Neurology · doi:10.1002/ana.25236 · Cited by 64 · see citing works
Panza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41 · see citing works
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B., Salvador, J. A. R., & Santos, A. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240146 · Cited by 33 · see citing works
Tremblay, G., Rousseau, J., Mbakam, C. H., & Tremblay, J. P. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0085 · Cited by 37 · see citing works
Şatır, T. M., Agholme, L., Karlsson, A., Karlsson, M., Karila, P., Illes, S., Bergström, P., & Zetterberg, H. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00635-0 · Cited by 33 · see citing works
Vassar, R. J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.3 · Cited by 32 · see citing works
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor
McKinzie, D. L., Winneroski, L. L., Green, S. J., Hembre, E. J., Erickson, J. A., Willis, B. A., Monk, S. A., Aluise, C. D., Baker, T. K., López, J. E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00489 · Cited by 31 · see citing works
The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer’s Disease
Xia, Q., Yang, X., Shi, J., Liu, Z., Peng, Y., Wang, W., Li, B., Zhao, Y., Xiao, J., Huang, L. F., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02385-y · Cited by 28 · see citing works
BACE1 partial deletion induces synaptic plasticity deficit in adult mice
Lombardo, S., Chiacchiaretta, M., Tarr, A. J., Kim, W., Cao, T., Sigal, G., Rosahl, T. W., Xia, W., Haydon, P. G., Kennedy, M. E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56329-7 · Cited by 28 · see citing works
Neumann, U., Machauer, R., & Shimshek, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14582 · Cited by 27 · see citing works
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 26 · see citing works
Decreased plasma C‐reactive protein levels in APOE ε4 allele carriers
Martiskainen, H., Takalo, M., Solomon, A., Stančáková, A., Marttinen, M., Natunen, T., Haapasalo, A., Herukka, S., Kuusisto, J., Soininen, H. S., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.639 · Cited by 25 · see citing works
Self-citationWittrahm, R., Takalo, M., Kuulasmaa, T., Mäkinen, P. M., Mäkinen, P., Končarević, S., Fartzdinov, V., Selzer, S., Kokkola, T., Antikainen, L., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106140 · Cited by 21 · see citing works
Self-citationBACE Inhibitor Clinical Trials for Alzheimer’s Disease
Watkins, E. A., & Vassar, R. J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231258 · Cited by 23 · see citing works
Guyon, A., Rousseau, J., Lamothe, G., & Tremblay, J. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237122 · Cited by 20 · see citing works
Ulku, I., Leung, R., Herre, F., Walther, L., Shobo, A., Säftig, P., Hancock, M. A., Liebsch, F., & Multhaup, G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107510 · Cited by 20 · see citing works
Alzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 19 · see citing works
Resende, R., Ferreira-Marques, M., Moreira, P., Coimbra, J. R. M., Baptista, S. J., Isidoro, C., Salvador, J. A. R., Dinis, T., Pereira, C., & Santos, A. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200381 · Cited by 12 · see citing works
Marttinen, M., Ferreira, C. B., Paldanius, K. M. A., Takalo, M., Natunen, T., Mäkinen, P. M., Leppänen, L., Leinonen, V., Tanigaki, K., Kang, G., et al. (2020) · Cells · doi:10.3390/cells9112482 · Cited by 14 · see citing works
Self-citationLehtonen, Š., Höytyläinen, I., Voutilainen, J., Sonninen, T.-M., Kuusisto, J., Laakso, M., Hämäläinen, R. H., Oksanen, M., & Koıstınaho, J. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.05.014 · Cited by 12 · see citing works
Self-citationThe Icelandic Mutation (APP-A673T) Is Protective against Amyloid Pathology In Vivo
Shimohama, S., Fujioka, R., Mihira, N., Sekiguchi, M., Sartori, L., Joho, D., Saito, T., Saido, T. C., Nakahara, J., Hino, T., et al. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.0223-24.2024 · Cited by 9 · see citing works
BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease
Ohno, M. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111475 · Cited by 12 · see citing works
Ohno, M. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12174 · Cited by 11 · see citing works
Ohno, M. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1161875 · Cited by 9 · see citing works
Siddiqui, F., Mishra, P., Khanam, S., Ranjan, S., Alam, P., Albalawi, T., Khan, S., & Mir, S. S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70142 · Cited by 8 · see citing works
Willis, B. A., Lowe, S. L., Monk, S. A., Cocke, P. J., Aluise, C. D., Boggs, L. N., Borders, A. R., Brier, R. A., Dean, R. A., Green, S. J., et al. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210037 · Cited by 8 · see citing works
Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model
Hampel, H. J., Lista, S., Caruso, G., Nisticò, R., Piccioni, G., Mercuri, N. B., Giorgi, F. S., Ferrarelli, F., Lemercier, P., Caraci, F., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211201095701 · Cited by 6 · see citing works
Stanciu, G. D., Ababei, D. C., Rusu, R.-N., Bild, V., & Tamba, B.-I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061270 · Cited by 6 · see citing works
Ohno, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231451 · Cited by 5 · see citing works
Bartolić, M., & Bosak, A. (2025) · BioFactors · doi:10.1002/biof.70071 · Cited by 4 · see citing works
Gao, F., Zhang, M., Wang, Q., Ni, M., Liu, C., Deng, K., Xie, Q., Wang, S., Shi, J., & Shen, Y. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02750-w · Cited by 4 · see citing works
BACE1 at the crossroads of a vicious circle between Alzheimer’s disease and diabetes mellitus
Ohno, M. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1730524 · Cited by 3 · see citing works
Understanding Neurodegenerative Diseases From the −Omics Perspective: Lessons Learnt
Ibáñez, L., Pottier, C. P., Beric, A., Western, D., Ali, M., & Cruchaga, C. (2026) · Annals of Neurology · doi:10.1002/ana.78170 · Cited by 4 · see citing works
Tarif, A. M. M., Huhe, H., & Ohno, M. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06525-9 · Cited by 3 · see citing works
Finnish neuroscience from past to present
Korpi, E. R., Lindholm, D., Panula, P., Tienari, P. J., & Haltia, M. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14693 · Cited by 3 · see citing works
Effect of the Icelandic Mutation APPA673T in the Murine APP Gene on Phenotype of Line 66 Tau Mice
Anschuetz, A., Robinson, L., Mondésir, M., Melis, V., Platt, B., Harrington, C. R., Riedel, G., & Schwab, K. (2025) · Biomolecules · doi:10.3390/biom16010028 · Cited by 2 · see citing works
Anschuetz, A., Listyono, R., Vorley, T., Platt, B., Harrington, C. R., Riedel, G., & Schwab, K. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin48581 · Cited by 1 · see citing works
The effect of the Icelandic mutation APP A673T in the line 66 model of tauopathyPreprint
Anschuetz, A., Robinson, L., Mondésir, M., Melis, V., Platt, B., Harrington, C. R., Riedel, G., & Schwab, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.09.681356 · Cited by 1 · see citing works
Genetic Risk Factors for Complex Forms of Alzheimer’s Disease
Bellenguez, C., & Lambert, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_4
Schröder, H., de Vos, R. A. I., Huggenberger, S., Müller-Thomsen, L., Rozemüller, A. J. M., Hedayat, F., & Moser, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-89980-6_13
Treating Alzheimer’s and ATTR using CRISPR-Cas9 to target amyloidosis
Joshi, P., Guilz, N. C., & Amendola, M. (2023) · Journal of Student Research · doi:10.47611/jsrhs.v12i3.4806
The Icelandic mutation APPA673T on amyloid-β plaque burden in the 5xFAD Alzheimer modelPreprint
Anschuetz, A., Listyono, R., Vorley, T., Platt, B., Harrington, C. R., Riedel, G., & Schwab, K. (2025) · bioRxiv · doi:10.1101/2025.11.05.686739
Upadhyay, K. D., Viramgami, A., Singh, D., Kulkarni, N., Chudasama, B., Sivaperumal, P., & Balachandar, R. (2025) · Research Square · doi:10.21203/rs.3.rs-7788186/v1
Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population
Russell, J. K., Schlachetzki, Z., & Rafii, M. S. (2026) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001461
Studying the role of human Amyloid Precursor Protein (APP) during human cortical neurogenesis
Shabani, K. (2021) · theses.fr (ABES) · doi:10.70675/2deeb337z2d8ez4a8dzaf55z268de3428ac9
Béguin, A. (2024) · doi:10.70675/91026eb5zf996z44a3zad54z8065cd33958b
Zakaria, J. A. D., & Vassar, R. J. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_188
Ahmad, W., Zhu, X., Khan, S. S., Bai, Y., & Pei, P. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-11068-x
- Authors
- Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M.
- Affiliations
- University of Eastern Finland (FI)
- Corresponding author
- Hiltunen, Mikko
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2017-07
- Volume
- 82
- Issue
- 1
- Pages
- 128-132
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2620291817
- Cited by
- 64
- References
- 19
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 8 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 3
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Academy of Finland (V16001)
- Kuopio University Hospital
- Sigrid Jusélius Foundation
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, plasma amyloid-beta, Aβ40, amyloid-beta 42, genetic risk variants, protective genetic variants, cardiovascular health, metabolic health, middle-aged and older men
- MeSH terms
- Alzheimer Disease, Heterozygote, Humans, Male, Middle Aged, Mutation, Peptide Fragments, Case-Control Studies, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, ATP-Binding Cassette Transporters, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
